North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 - MarketsandMarkets

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 - MarketsandMarkets
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017
Published Apr 18, 2013
282 pages — Published Apr 18, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

North American Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

North American Radiopharmaceutical and Stable Isotope Markets, By Country

U.S.
Canada

Customer Interested in this report also can view

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Trends & Forecast to 2017
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable I

  
Source:
Document ID
PH 1868
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Contents

1 Introduction (Page No.- 26)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No.- 33)

3 Market Overview (Page No.- 37)
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In The Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals To Restrict Usage
3.4.2.2 High Capital Demand To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Ample Number Of Potential Radioisotopes In The Pipeline
3.4.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.4.3.3 Alternative Diagnostic Radiopharmaceuticals Solution
3.4.3.4 Cyclotron-Based Production
3.4.3.5 Neurological Application
3.4.4 Threat
3.4.4.1 Shutdown Of Nuclear Reactors Impacts The Production Of Radioisotopes
3.5 Winning Imperatives
3.5.1 Investment To Encourage New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Shortage In Supply Of Technetium-99m
3.7 Supply And Demand Analysis Of Technetium-99m
3.8 Regulatory Affairs
3.8.1 U.S.
3.8.1.1 Fda Approval Process
3.8.1.2 Transportation
3.8.1.3 Reimbursement Scenario
3.8.2 Canada
3.8.2.1 Nuclear Safety And Control Act
3.8.2.2 Transportation
3.8.2.3 Licensing
3.9 Market Share Analysis
3.9.1 Radiopharmaceuticals Market
3.9.2 Enriched Stable Isotopes Market

4 North American Radiopharmaceuticals Market, By Isotope (Page No.- 61)
4.1 Introduction
4.2 Diagnostic Isotopes
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (Spect) Radiopharmaceuticals
4.2.2.1 Technetium-99m (TC-99M)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (TL-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (GA-67)
4.2.2.3.1 Fluorine-18 Might Seize GA-67 Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others
4.2.3 Positron Emission Tomography (PET) Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 FDG
4.2.3.1.2 Florbetapir
4.2.3.1.3 Factors Affecting Fluorine-18 Market

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" Apr 18, 2013. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/North-American-Nuclear-Medicine-Radiopharmaceuticals-Stable-Isotopes-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Deuterium-C-13-Forecast-to-2017-2144-103>
  
APA:
MarketsandMarkets. (2013). North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 Apr 18, 2013. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/North-American-Nuclear-Medicine-Radiopharmaceuticals-Stable-Isotopes-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Deuterium-C-13-Forecast-to-2017-2144-103>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.